Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

被引：5
|
作者：
Lim, Jonathan [1 ]
Samuelsen, Carl [2 ]
Golembesky, Amanda [2 ]
Shrestha, Sulena [3 ]
Wang, Li [3 ]
Griebsch, Ingolf [2 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[3] STATinMED Res, Plano, TX 75024 USA
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 13期
关键词：
afatinib; EGFR tyrosine kinase inhibitors; erlotinib; first-line treatment; non-small-cell lung cancer; KINASE INHIBITOR-AFATINIB; HEALTH-CARE UTILIZATION; OPEN-LABEL; PHASE-III; REAL-WORLD; CARBOPLATIN-PACLITAXEL; ACQUIRED-RESISTANCE; TREATMENT PATTERNS; CHANNELING BIAS; GEFITINIB;
D O I：
10.2217/fon-2019-0052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Evaluate duration of therapy among patients treated with afatinib or erlotinib as first-line therapy for non-small-cell lung cancer (NSCLC). Materials & methods: NSCLC patients initiating afatinib or erlotinib between 2014 and 2017 were identified in three large claims databases in the USA. Propensity score matching was conducted to compare the duration of treatment between patients by treatment. Results: Patients prescribed afatinib had a significantly longer median duration of treatment compared with those prescribed erlotinib (12.1 vs 9.9 months; p = 0.035) and experienced a 14% reduction in risk of discontinuing therapy (adjusted hazard ratio: 0.86; CI: 0.75-0.99). Conclusion: First-line treatment duration in a real-world setting was significantly longer for patients prescribed afatinib compared with erlotinib.
引用
收藏
页码：1493 / 1504
页数：12
相关论文
共 50 条
  • [21] Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
    Lee, Sung Yong
    Choi, Chang-Min
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Ji Young
    Kim, Young-Chul
    Oh, In-Jae
    Jung, Chi Young
    Lee, Sang Hoon
    Yoon, Seong Hoon
    Choi, Juwhan
    Jang, Tae Won
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (12) : 4353 - +
  • [22] Erlotinib in the first-line treatment of non-small-cell lung cancer
    D'Arcangelo, Manolo
    Cappuzzo, Federico
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
  • [23] Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib
    Horn, Leora
    Gettinger, Scott
    Camidge, D. Ross
    Smit, Egbert F.
    Janjigian, Yelena Y.
    Miller, Vincent A.
    Pao, William
    Freiwald, Matthias
    Fan, Jean
    Wang, Bushi
    Chand, Vikram K.
    Groen, Harry J. M.
    LUNG CANCER, 2017, 113 : 51 - 58
  • [24] Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
    Bennouna, Jaafar
    FUTURE ONCOLOGY, 2017, 13 (21) : 1829 - 1833
  • [25] Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
    Engle, Jeff
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (22) : 1933 - 1938
  • [26] Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients
    Wu, Ting-Hui
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Liao, Wei-Yu
    Ho, Chao-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    CLINICAL LUNG CANCER, 2018, 19 (03) : E361 - E372
  • [27] Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Nakagawa, Kazuhiko
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (11)
  • [28] COST-EFFECTIVENESS OF AFATINIB, ERLOTINIB, AND CISPLATIN/PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC EGFR-MUTATION POSITIVE NON-SMALL CELL LUNG CANCER
    Ting, J.
    Ho, T.
    Xiang, P.
    Abdel-Sattar, M.
    Sugay, A.
    Wilson, L. S.
    VALUE IN HEALTH, 2014, 17 (03) : A84 - A84
  • [29] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [30] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
    Kim, Mi-Hyun
    Choi, Chang Min
    Lee, Sung Yong
    Park, Cheol Kyu
    Chang, Yoon Soo
    Lee, Kye Young
    Kim, Seung Joon
    Yang, Sei Hoon
    Ryu, Jeong Seon
    Lee, Jeong Eun
    Lee, Shin Yup
    Park, Chan Kwon
    Lee, Sang Hoon
    Jang, Seung Hun
    Yoon, Seong Hoon
    Jang, Tae Won
    ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622
12345